[ad_1] RT @ThomasCiullaMD: The @RetinalPhys special issue on #suprachoroidal #drugdelivery highlights its versatility with articles on biomechanic… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] OCT has revolutionized clinical #ophthalmology, given its rapid noninvasive assessment of the cross-sectional structure of the #retina. Here, we discuss #oct #biomarkers proposed as measures of disease severity and visual prognosis in uveitic macular edema… https://t.co/EaEPoH1Nxr [ad_2] Source by Thomas Ciulla, MD, MBA Return …
[ad_1]
RT @ThomasCiullaMD: Congrats to colleagues & partners with numerous presentations involving #suprachoroidal delivery at last week’s @OISTW…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] The @RetinalPhys special issue on #suprachoroidal #drugdelivery highlights its versatility with articles on biomechanics, #clinicaltrials in FDA-approval of #Xipere for uveitic macular edema, & potential in ocular oncology therapy & #genetherapy delivery. https://t.co/2YSkxZH5pi [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @ThomasCiullaMD: Just published: With the recent FDA-approval of #Xipere, clinicians are increasingly interested in Uveitic Macular Edem… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @ModernRetina: Survey respondents point to a perceived gap in treatments for uveitic macular edema, document interest in suprachoroidal…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @OphthTimes: Triamcinolone acetonide injectable suspension (Xipere, Bauch + Lomb) was launched recently as the first and only therapy ap… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] Just published: With the recent FDA-approval of #Xipere, clinicians are increasingly interested in Uveitic Macular Edema, the most common cause of vision loss in #uveitis. OCT Biomarkers in Uveitic Macular Edema on @RetinaToday https://t.co/T0JqXtkqf9 [ad_2] Source by Thomas Ciulla, MD, MBA Return to main …
[ad_1]
Congrats to colleagues & partners with numerous presentations involving #suprachoroidal delivery at last week’s @OISTWEETS & #ASRS meetings!
In addition to FDA-approved #Xipere, 6 trials globally are assessing 4 different investigational therapies, using the SCS Microinjector. https://t.co/g8QZgV3Fp0
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @ModernRetina: WATCH: Charles Wykoff, MD, discusses, “Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: Phase II… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.